Clinical trials: SARS-COV2
COVID-19
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
- Trial name
- NCT04397757
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19
Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19
Resveratrol is a plant polyphenol (that is sold commercially as a supplement) that might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection.
- Trial name
- NCT04400890
- Testing
- Resveratrol, Vitamin D3
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Marvin McCreary, MD
COVID-19, Corona Virus Infection
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
This study will evaluate the safety of administering an additional dose of an mRNA COVID-19 vaccine or mRNA bivalent COVID-19 booster vaccine to individuals who have had adverse reactions to a previous dose or administering an…
- Trial name
- NCT05212610
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Michigan
Covid19, Coronavirus
SPI-1005 Treatment in Severe COVID-19 Patients
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19…
- Conditions
- Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
- Trial name
- NCT04483973
- Testing
- Ebselen
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Coronavirus Infection
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive…
- Trial name
- WU352 (NCT04341727)
- Testing
- Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
COVID
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Interventional, randomized, double-blind, placebo-controlled study encompassing 2 development phases (Phase 2 and Phase 3).
- Trial name
- NCT04447469
- Testing
- mavrilimumab
- Where
- 32 sites in United States, Brazil and 3 more
- Volunteers
- 814 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc
Covid19
UPMC OPTIMISE-C19 Trial, a COVID-19 Study
Multiple monoclonal antibodies (mABs) have been shown to reduce viral burden and improve clinical outcomes, have been granted FDA Emergency Use Authorization (EUA) for use in select populations, and are routinely used in the UPMC…
- Trial name
- OPTIMISE-C19 (NCT04790786)
- Testing
- Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab
- Where
- United States
- Volunteers
- 4,571 people
- Sponsor
- Erin McCreary
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
This is a Phase 1/2, randomized, placebo-controlled, and observer-blind study in healthy Japanese adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against…
- Trial name
- NCT04588480
- Testing
- BNT162b2
- Where
- 2 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, SARS-CoV-2
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
- Trial name
- NCT04472494
- Testing
- Abatacept
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
Increased Risk of SARS-CoV-2 Infection
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting…
- Trial name
- NCT04405999
- Testing
- Bromhexine Hydrochloride
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Sars-CoV-2, Covid19
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability…
- Trial name
- NCT04334460
- Testing
- BLD-2660
- Where
- 35 sites in United States, Brazil
- Volunteers
- 120 people
- Sponsor
- Blade Therapeutics
COVID
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19.
- Trial name
- NCT04382924
- Testing
- NP-120 (Ifenprodil)
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- Algernon Pharmaceuticals
Long COVID, Long Covid19
RECOVER-AUTONOMIC Platform Protocol
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Trial name
- NCT06305780
- Testing
- IVIG + Coordinated Care, Ivabradine + Coordinated Care, IVIG + Usual Care
- Where
- 50 sites in United States
- Volunteers
- 381 people
- Sponsor
- Kanecia Obie Zimmerman
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
COVID-19 Disease
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An open label phase 2 trial to evaluate safety, tolerability and immunogenicity of the ABNCoV2 vaccine after intramuscular (IM) application.
- Trial name
- NCT05077267
- Testing
- ABNCoV2 100ug, ABNCoV2 50ug
- Where
- 2 sites in Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the…
- Trial name
- ENSEMBLE 2 (NCT04614948)
- Testing
- Ad26.COV2.S
- Where
- 126 sites in United States, Belgium and 8 more
- Volunteers
- 31,835 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.